DOI: 10.1055/s-00000020

Geburtshilfe und Frauenheilkunde

References

Saura C, Oliveira M, Feng YH. et al.
Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.

J Clin Oncol 2019;
DOI: 10.1200/JCO.2019.37.15:suppl.1002.

Download Bibliographical Data

Search in:
Access: